Information:
Fel:
ID
33930
Beskrivning
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02328261
Länk
https://clinicaltrials.gov/show/NCT02328261
Nyckelord
Versioner (1)
- 2019-01-08 2019-01-08 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
8 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Nasopharyngeal Carcinoma NCT02328261
Eligibility Nasopharyngeal Carcinoma NCT02328261
- StudyEvent: Eligibility
Similar models
Eligibility Nasopharyngeal Carcinoma NCT02328261
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Nasopharyngeal carcinoma Advanced
Item
histologically confirmed advanced npc
boolean
C2931822 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,2])
Platinum Resistant | Recurrent disease | Disease Progression
Item
patients must be platinum-resistant defined as recurrence or progression of disease <6 months since previous treatment with a platinum based treatment regimen.
boolean
C0032207 (UMLS CUI [1,1])
C0332325 (UMLS CUI [1,2])
C0277556 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
C0332325 (UMLS CUI [1,2])
C0277556 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
Measurable Disease
Item
measurable disease per recist
boolean
C1513041 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
adequate organ and marrow function
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
Protocol Compliance | Informed Consent
Item
capable of understanding and complying with the protocol, and written informed consent
boolean
C0525058 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0021430 (UMLS CUI [2])
gefitinib | erlotinib | Pharmaceutical Preparations Targeting Epidermal Growth Factor Receptor
Item
prior treatment with gefitinib, erlotinib, or other drugs that target egfr
boolean
C1122962 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0034802 (UMLS CUI [3,3])
C1135135 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0034802 (UMLS CUI [3,3])
Investigational New Drugs
Item
patients must not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1])
Illness Serious Treatment required for | Medical condition Treatment required for | Heart Diseases Unstable | Nervous system disorder | Mental disorders | Psychotic Disorders | Dementia | Seizures | Communicable Disease Uncontrolled
Item
other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C0018799 (UMLS CUI [3,1])
C0443343 (UMLS CUI [3,2])
C0027765 (UMLS CUI [4])
C0004936 (UMLS CUI [5])
C0033975 (UMLS CUI [6])
C0497327 (UMLS CUI [7])
C0036572 (UMLS CUI [8])
C0009450 (UMLS CUI [9,1])
C0205318 (UMLS CUI [9,2])
C0205404 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C0018799 (UMLS CUI [3,1])
C0443343 (UMLS CUI [3,2])
C0027765 (UMLS CUI [4])
C0004936 (UMLS CUI [5])
C0033975 (UMLS CUI [6])
C0497327 (UMLS CUI [7])
C0036572 (UMLS CUI [8])
C0009450 (UMLS CUI [9,1])
C0205318 (UMLS CUI [9,2])
Pregnancy | Breast Feeding
Item
women who are pregnant or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])